It also demonstrated that pharmacological targeting of SphK1 offers a novel strategy for inhibiting tumor angiogenesis by disrupting glycolytic energy production, with potential significance for the development of effective HCC treatments. The gene discussed is SPHK1; the disease is hepatocellular carcinoma.